聚腺苷二磷酸核糖聚合酶抑制剂在胰腺癌中的应用。
PARP Inhibitors in Pancreatic Cancer.
机构信息
From the Abramson Cancer Center, The University of Pennsylvania, Philadelphia, PA.
出版信息
Cancer J. 2021;27(6):465-475. doi: 10.1097/PPO.0000000000000554.
Abstract
Despite representing only 5% of all annual cancer diagnoses in the United States, pancreatic cancer is projected to become the second leading cause of cancer-related death within the next 10 years. Progress in the treatment of advanced pancreatic cancer has been slow. Systemic therapies rely on combination cytotoxic agents, with limited options at progression. Recently, poly(ADP-ribose) polymerase inhibitors have demonstrated clinical activity in patients with advanced pancreatic cancer and pathogenic variants in BRCA1, BRCA2, and PALB2. In this review, we discuss the development of poly(ADP-ribose) polymerase inhibitors in pancreatic cancer, relevant clinical trials, and future directions.
摘要
尽管在美国所有年度癌症诊断中仅占 5%，但预计在未来 10 年内，胰腺癌将成为第二大致癌相关死亡原因。晚期胰腺癌的治疗进展缓慢。系统疗法依赖于联合细胞毒性药物，在进展时选择有限。最近，聚（ADP-核糖）聚合酶抑制剂在携带 BRCA1、BRCA2 和 PALB2 种系变异的晚期胰腺癌患者中显示出临床活性。在这篇综述中，我们讨论了聚（ADP-核糖）聚合酶抑制剂在胰腺癌中的开发、相关临床试验和未来方向。
相似文献
1
PARP Inhibitors in Pancreatic Cancer.聚腺苷二磷酸核糖聚合酶抑制剂在胰腺癌中的应用。
Cancer J. 2021;27(6):465-475. doi: 10.1097/PPO.0000000000000554.
2
PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.聚腺苷二磷酸核糖聚合酶抑制剂：改变胰腺癌治疗模式。
Med Oncol. 2021 Apr 23;38(6):61. doi: 10.1007/s12032-021-01507-9.
3
mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance.mTORC2 促进胰腺癌进展和 PARP 抑制剂耐药性。
Oncol Res. 2023 Jun 27;31(4):495-503. doi: 10.32604/or.2023.029309. eCollection 2023.
4
mutated pancreatic cancer: A change is coming.突变型胰腺癌：变革即将来临。
World J Gastroenterol. 2021 May 7;27(17):1943-1958. doi: 10.3748/wjg.v27.i17.1943.
5
Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.聚（ADP-核糖）聚合酶抑制剂在胰腺癌中的应用。
Genes Chromosomes Cancer. 2021 May;60(5):373-384. doi: 10.1002/gcc.22932. Epub 2021 Jan 9.
6
Rapid Progression of Metastatic Pancreatic Adenocarcinoma During Platinum-Based Therapy in a Patient Harboring a Pathogenic BRCA2 Germline Variant.携带致病性 BRCA2 种系变异的患者在铂类药物治疗期间转移性胰腺导管腺癌的快速进展。
Oncologist. 2021 Nov;26(11):916-918. doi: 10.1002/onco.13912. Epub 2021 Aug 6.
7
The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.聚腺苷二磷酸核糖聚合酶抑制剂在种系 BRCA 相关胰腺导管腺癌中的作用。
Clin Adv Hematol Oncol. 2020 Mar;18(3):168-179.
8
PARP-inhibitors in BRCA-associated pancreatic cancer.PARP抑制剂在BRCA相关胰腺癌中的应用
JOP. 2014 Jul 28;15(4):340-3. doi: 10.6092/1590-8577/2690.
9
PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.PARP 抑制剂在胰腺癌中的应用：分子机制与临床应用。
Mol Cancer. 2020 Mar 2;19(1):49. doi: 10.1186/s12943-020-01167-9.
10
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions.用于BRCA1/2突变型和散发性卵巢癌的PARP抑制剂：当前实践与未来方向
Br J Cancer. 2016 Nov 8;115(10):1157-1173. doi: 10.1038/bjc.2016.311. Epub 2016 Oct 13.
引用本文的文献
1
Preliminary evaluation of ShallowHRD performance compared to HRDetect in familial breast cancer tumors.与HRDetect相比，ShallowHRD在家族性乳腺癌肿瘤中的性能初步评估。
Sci Rep. 2025 Aug 11;15(1):29442. doi: 10.1038/s41598-025-14122-9.
2
Pancreatic ductal adenocarcinoma: the Everest of cancer biology.胰腺导管腺癌：癌症生物学中的珠穆朗玛峰。
J Clin Invest. 2025 Jul 15;135(14). doi: 10.1172/JCI191936.
3
Germline DNA Repair Gene Mutations and Clonal Hematopoiesis (CH) in 24,849 Patients with BRCA-Associated Cancers.24849例BRCA相关癌症患者的生殖系DNA修复基因突变与克隆性造血（CH）
Cancers (Basel). 2025 Apr 25;17(9):1432. doi: 10.3390/cancers17091432.
4
Pancreatic cancer: failures and hopes-a review of new promising treatment approaches.胰腺癌：失败与希望——新的有前景的治疗方法综述
Explor Target Antitumor Ther. 2025 Mar 18;6:1002299. doi: 10.37349/etat.2025.1002299. eCollection 2025.
5
Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer.研究胰腺癌潜在的分子机制、信号通路及新出现的治疗方法。
Front Oncol. 2024 Jul 17;14:1427802. doi: 10.3389/fonc.2024.1427802. eCollection 2024.
6
Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells.改性间充质干细胞作为靶向系统对抗肿瘤细胞的应用。
Int J Mol Sci. 2024 Jul 16;25(14):7791. doi: 10.3390/ijms25147791.
7
Nimbolide: A Potential Phytochemical Agent in Multimodal Pancreatic Cancer Therapies.印楝素：多模式胰腺癌治疗中的一种潜在植物化学药物。
Mini Rev Med Chem. 2025;25(1):27-41. doi: 10.2174/0113895575293138240527061556.
8
Genetic Signature of Human Pancreatic Cancer and Personalized Targeting.人类胰腺癌细胞的遗传特征与个体化靶向治疗
Cells. 2024 Mar 29;13(7):602. doi: 10.3390/cells13070602.
9
Targeting BRCA and PALB2 in Pancreatic Cancer.针对胰腺癌中的 BRCA 和 PALB2。
Curr Treat Options Oncol. 2024 Mar;25(3):346-363. doi: 10.1007/s11864-023-01174-0. Epub 2024 Jan 4.
10
Feasibility and effectiveness of automatic deep learning network and radiomics models for differentiating tumor stroma ratio in pancreatic ductal adenocarcinoma.自动深度学习网络和放射组学模型用于区分胰腺导管腺癌肿瘤间质比例的可行性和有效性
Insights Imaging. 2023 Dec 21;14(1):223. doi: 10.1186/s13244-023-01553-z.
本文引用的文献
1
A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (The APOLLO Trial).奥拉帕利或安慰剂用于接受手术切除的携带BRCA1、BRCA2或PALB2基因突变的胰腺癌患者的随机研究（APOLLO试验）。
Ann Surg Oncol. 2022 Sep;29(9):5375-5376. doi: 10.1245/s10434-022-11917-2. Epub 2022 Jun 6.
2
Retrospective Survival Analysis of Patients With Resected Pancreatic Ductal Adenocarcinoma and a Germline or Mutation.接受切除的胰腺导管腺癌合并种系或体细胞突变患者的回顾性生存分析
JCO Precis Oncol. 2019 Dec;3:1-11. doi: 10.1200/PO.18.00271.
3
Understanding and overcoming resistance to PARP inhibitors in cancer therapy.理解和克服癌症治疗中对 PARP 抑制剂的耐药性。
Nat Rev Clin Oncol. 2021 Dec;18(12):773-791. doi: 10.1038/s41571-021-00532-x. Epub 2021 Jul 20.
4
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.胰腺癌同源重组缺陷：系统评价和患病率荟萃分析。
J Clin Oncol. 2021 Aug 10;39(23):2617-2631. doi: 10.1200/JCO.20.03238. Epub 2021 Jul 1.
5
A first-in-class Polymerase Theta Inhibitor selectively targets Homologous-Recombination-Deficient Tumors.一种一流的聚合酶θ抑制剂选择性靶向同源重组缺陷型肿瘤。
Nat Cancer. 2021 Jun;2(6):598-610. doi: 10.1038/s43018-021-00203-x. Epub 2021 Jun 17.
6
Rationale for combination PARP inhibitor and antiangiogenic treatment in advanced epithelial ovarian cancer: A review.PARP抑制剂与抗血管生成治疗联合用于晚期上皮性卵巢癌的理论依据：综述
Gynecol Oncol. 2021 Aug;162(2):482-495. doi: 10.1016/j.ygyno.2021.05.018. Epub 2021 Jun 3.
7
ATR inhibition amplifies antitumor effects of olaparib in biliary tract cancer.ATR抑制增强了奥拉帕尼在胆管癌中的抗肿瘤作用。
Cancer Lett. 2021 Sep 28;516:38-47. doi: 10.1016/j.canlet.2021.05.029. Epub 2021 May 31.
8
Adjuvant Olaparib for Patients with - or -Mutated Breast Cancer.奥拉帕利辅助治疗 - 或 - 突变型乳腺癌患者。
N Engl J Med. 2021 Jun 24;384(25):2394-2405. doi: 10.1056/NEJMoa2105215. Epub 2021 Jun 3.
9
Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in , , or .铂敏感的晚期胰腺癌且存在种系或体细胞致病变体的患者中，维持使用鲁卡帕尼的II期研究。 （注：原文中“in , , or .”部分内容缺失，以上是按完整句子结构翻译的大致内容）
J Clin Oncol. 2021 Aug 1;39(22):2497-2505. doi: 10.1200/JCO.21.00003. Epub 2021 May 10.
10
Pancreatic Adenocarcinoma, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.胰腺导管腺癌临床实践指南（第 2.2021 版），NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2021 Apr 1;19(4):439-457. doi: 10.6004/jnccn.2021.0017.
Zotero 插件